Inclacumab is under clinical development by Global Blood Therapeutics and currently in Phase III for Sickle Cell Disease With Vaso-Occlusive Crisis. According to GlobalData, Phase III drugs for Sickle Cell Disease With Vaso-Occlusive Crisis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Inclacumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Inclacumab overview

Inclacumab is under development for the treatment of vaso-occlusive crisis in patients with sickle cell disease. The drug candidate is a monoclonal antibody and is administered intravenously. RG1512 targets P-selectin.

It was under development for the treatment of acute coronary syndrome, myocardial infarction in patients undergoing percutaneous coronary intervention and prevention of saphenous vein graft disease and peripheral vascular disease/peripheral arterial disease (PAD).

Global Blood Therapeutics overview

Global Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company. The company offers Voxelotor which is used for the treatment of sickle cell disease, or SCD, in adults and children. GBT’s pipeline also includes GBT021601 which is a next-generation hemoglobin polymerization inhibitor that is in Phase 1 development. The company also develops therapies that are in preclinical and preliminary clinical stages for the treatment of acute and chronic hypoxemic pulmonary disorders. It offers chemical and biological mechanisms for blood-based disorders. GBT is headquartered in South San Francisco, California, the US.

For a complete picture of Inclacumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.